HealthPlus Retail Group — Executive Summary
HealthPlus Retail Group seeks ZAR 2.8 billion to build a vertically integrated pharmaceutical retail, distribution and health-and-beauty chain in South Africa — a 26–32% IRR opportunity scaling to 450+ stores and ZAR 9.2 billion revenue by Year 5 at a 17.6% EBITDA margin.
Section 1 · Business Plan
Executive Summary
HealthPlus Retail Group seeks ZAR 2.8 billion to build a vertically integrated pharmaceutical retail, distribution and health-and-beauty chain in South Africa — a 26–32% IRR opportunity scaling to 450+ stores and ZAR 9.2 billion revenue by Year 5 at a 17.6% EBITDA margin.
1.1 The Investment Opportunity
HealthPlus Retail Group (Pty) Ltd (“HealthPlus” or the “Company”) is
a newly capitalised pharmaceutical retail and distribution platform
designed to capture significant share of South Africa’s R72 billion
pharmaceutical and health-and-beauty retail market. The Company will
operate an integrated, vertically structured business comprising
community pharmacies, in-store primary healthcare clinics, a
private-label manufacturing arm, a wholesale pharmaceutical distribution
unit, and a digital-first loyalty ecosystem.
The Company seeks ZAR 2.8 billion in growth capital — comprising
senior debt, mezzanine, and equity instruments — to fund a 60-month
rollout culminating in 450+ retail outlets, three regional distribution
centres, a private-label manufacturing facility, and an active loyalty
base of 8 to 10 million South African households. At maturity (Year 5),
the Company is projected to generate ZAR 9.2 billion in annual revenue
and ZAR 1.6 billion in EBITDA, delivering an equity IRR of 26% to 32%
over a typical investment horizon.
technology-enabled, value-driven pharmaceutical retailer in Southern
Africa — an essential infrastructure platform for healthcare delivery in
an underserved market.
1.2 Headline Metrics
1.3 Why South Africa, Why Now
South Africa’s pharmaceutical retail sector represents one of the
most attractive consumer healthcare opportunities on the African
continent. Three structural forces converge to create a generational
opportunity for a well-capitalised, professionally managed entrant:
- A defensive, non-cyclical category. Pharmaceutical demand is
largely insulated from macroeconomic volatility. Even during the 2020
contraction and the 2023 load-shedding crisis, listed pharmacy retailers
grew turnover at high single-digit rates while broader retail
contracted. - Structural under-penetration outside Tier 1 cities. Approximately
22% of the formal pharmacy retail market remains in fragmented
independent ownership, concentrated in townships, peri-urban, and Tier
2/3 nodes where the leading chains have under-invested. - Demographic tailwinds. South Africa’s population is forecast to
expand from 62.0 million in 2024 to 67.5 million by 2030. The
middle-income segment is growing at 4.1% per annum (2024–2030 forecast),
and chronic-disease prevalence — diabetes, hypertension, HIV/AIDS,
mental health — is rising in line with global trends.
The South African pharmacy market has a clear duopoly at the top
(Clicks and Dis-Chem control approximately 58% of formal share) but
remains highly fragmented below the top tier. No challenger has yet
combined the scale, low-cost positioning, private-label depth, and
digital infrastructure required to consolidate the long tail. HealthPlus
is purpose-built to occupy this gap.
1.4 Strategic Architecture
HealthPlus operates on five mutually reinforcing strategic pillars,
designed to deliver high customer frequency, defensive margins, and
scalable unit economics:
| Pillar | Description | Margin / Frequency Driver |
|---|---|---|
| Pharmacy Anchor | Licensed dispensing pharmacies and primary-care clinics in every store | Traffic engine; high frequency |
| Health & Beauty Retail | Front-shop offer covering personal care, cosmetics, baby, wellness | Margin amplifier (>40% GP) |
| Private Label Programme | 25–30% of sales target via owned brands & exclusive licenses | Margin uplift +700–1,000 bps |
| Wholesale Distribution | B2B distribution to independents, clinics, and corporate accounts | Revenue diversification, scale |
| Digital & Loyalty | “PlusOne” mobile-first loyalty platform with cashback model | Lifetime value multiplier |
1.5 Financial Highlights
The following table summarises the projected five-year financial
performance under the base case scenario. Detailed assumptions,
sensitivities, and full three-statement projections are set out in
Section 10.
| ZAR Millions | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Number of Stores (period-end) | 30 | 100 | 210 | 345 | 450 |
| Revenue | 340 | 1,060 | 2,520 | 5,160 | 9,200 |
| Gross Profit | 97 | 331 | 852 | 1,837 | 3,395 |
| Gross Margin % | 28.5% | 31.2% | 33.8% | 35.6% | 36.9% |
| EBITDA | (28) | 48 | 297 | 795 | 1,619 |
| EBITDA Margin % | (8.2%) | 4.5% | 11.8% | 15.4% | 17.6% |
| Net Profit / (Loss) | (42) | (19) | 131 | 470 | 1,049 |
| Net Margin % | (12.4%) | (1.8%) | 5.2% | 9.1% | 11.4% |
| Operating Cash Flow | (280) | 75 | 480 | 1,240 | 2,380 |
| Loyalty Members (millions) | 0.3 | 1.2 | 3.5 | 6.5 | 9.2 |
1.6 Capital Structure & Use of Funds
The proposed capital structure has been engineered to optimise the
cost of capital while preserving flexibility through the high-investment
phase (Years 1–3). The Company will deploy a blended instrument stack:
senior secured debt for asset-backed capex (distribution centres and
manufacturing); mezzanine for store rollout working capital; and Series
A equity for brand building, technology, and growth investment.
| Instrument | Provider Type | Amount (ZAR M) | % |
|---|---|---|---|
| Series A Equity | Strategic & Financial Sponsors | 1,200 | 42.9% |
| Senior Secured Debt | Tier-1 SA Banks | 850 | 30.4% |
| Mezzanine / Sub Debt | DFI / PE Credit Funds | 450 | 16.1% |
| Working Capital Facility | Trade Finance Bank | 300 | 10.7% |
| Total | 2,800 | 100.0% |
1.7 Investor Value Proposition
The HealthPlus opportunity is differentiated by five
investor-relevant attributes:
- Defensive cash flows. Pharmaceuticals and primary healthcare are
essential, non-discretionary expenditure categories that perform across
economic cycles. - High visibility unit economics. Each store is projected to reach
EBITDA breakeven within 14 months of opening and full payback within
38–44 months. - Scalable platform. The technology stack, supply chain, and brand
architecture are designed to support a 1,000-store footprint and
expansion into the SADC region without structural
re-investment. - Multiple exit pathways. JSE listing, strategic sale to a
multinational consumer health group, or PE secondary are all credible by
Years 5–7. - Aligned ESG profile. Healthcare access, township employment, and
pharmaceutical affordability are aligned with development finance and
ESG-mandated capital pools.
The financial projections in this document are presented on a
base-case basis. Sensitivity analysis (Section 10.6) demonstrates that
even in a downside scenario — with same-store sales 200 bps lower and
gross margin 150 bps below plan — the platform retains a 17.8% equity
IRR. Upside scenarios driven by accelerated private-label penetration
deliver IRRs in excess of 35%.
1.8 Roadmap to Bankability
This Business Plan is organised to enable rapid investor due
diligence. Sections 2 to 4 establish the strategic and market context.
Sections 5 to 9 describe the operating model and execution plan.
Sections 10 to 14 present the full financial case, capital structure,
and investor returns. Section 15 provides supporting appendices
including detailed assumption schedules, regulatory frameworks, and the
data room index.
Management is available to engage qualified investors in due
diligence sessions, site visits to pilot locations once operational, and
discussions on the structuring of the proposed transaction. Indicative
term sheets are invited from interested parties by the date specified in
the cover communication accompanying this document.
Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of HealthPlus Retail Group (Pty) Ltd.